Aleksandra A Taube

Dr. Aleksandra A Taube

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2024 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
Verified
Journal Article
Open access
PDF file
AKA. A. Khalimova
A. A. Khalimova
AOA. S. Orlov
A. S. Orlov
ATAleksandra A Taube
Aleksandra A Taube
SCIENTIFIC RELEVANCE. Russia is pursuing a consistent government policy of import substitution and increasing the localisation of pharmaceutical manufacturing. The Strategy for the Development of the Pharmaceutical Industry until 2030 (Pharma-2030) includes the target share of medicinal products from the List of Strategic Medicines that should be fully localised. Since biotechnological medicinal products have high consumption growth rates and are listed as strategic medicines, it is a priority to study their production localisation process.AIM. This study aimed to analyse the degree of biopharmaceutical manufacturing localisation in Russia, considering the country of origin of active pharmaceutical ingredients (APIs).MATERIALS AND METHODS. The study used the State Register of Medicines and sales data of the DSM Group marketing agency. The authors used custom software for the Node.js® platform to determine the degree of production localisation.RESULTS. The analysis showed that the production process was fully localised for 25.6% (in packages) and 26.6% (in roubles) of all biotechnological medicinal products consumed in Russia in 2022. Imported medicinal products dominated the consumption structure, with a share of 33.9% in packages and 31.3% in roubles. Medicinal products with localised secondary packaging accounted for 5.8% in packages and 25.9% in roubles. Finished dosage forms produced using imported APIs had a significant share of 23.7% in packages and 6.2% in roubles. Russian APIs were used to produce 79% of the biotechnological medicinal products listed as strategic medicines, which corresponded to the full localisation of a share of the consumption structure of 10.8% in packages and 32.3% in roubles.CONCLUSIONS. The Russian biotechnological market remains heavily dependent on imported finished medicinal products and APIs. Although the Pharma-2030 target for the production of strategic biotechnological products has been achieved, the quantitative indicators show the necessity to increase output and localisation.

1 January 2021 in Вестник Смоленской государственной медицинской академии
Verified
Journal Article
Closed access
ATAleksandra A Taube
Aleksandra A Taube

20 April 2022 in Bulletin of the Russian Military Medical Academy
Verified
Journal Article
Open access
PDF file
ATAleksandra A Taube
Aleksandra A Taube
IEIrina Y. Evko
Irina Y. Evko
SSSvetlana V. Sinitova
Svetlana V. Sinitova
AKAnatoly E. Krasheninnikov
Anatoly E. Krasheninnikov
MZMarina V. Zhuravleva
Marina V. Zhuravleva
RARenad Alyautdin
Renad Alyautdin
The paper presents the results of a survey of pharmacovigilance specialists awareness of the regulation of reporting on adverse drug reactions, self-assessment of their competencies and readiness for distance learning, creation of a generalized portrait of a pharmacovigilance specialist to create mechanisms for improving pharmacovigilance activities, and continuing education of pharmacovigilance specialists. The results of the correlation analysis of the knowledge of pharmacovigilance specialists with their self-assessment of their position are reflected. Information-analytical and sociological (survey) methods and descriptive statistics were used. A questionnaire consisting of 31 items was developed for the survey. The first part of the questionnaire consisted of general questions, such as on education, work experience in the pharmaceutical field and pharmacovigilance, and position held. The second part focused on the structure of pharmacovigilance in the organization of holders of the registration certificate. The third part consisted of 17 items aimed at identifying the level of knowledge concerning the immediate daily activities in pharmacovigilance and knowledge of the legislative framework. The final element was a question about the attitude to distance learning. Specialists working in the field of pharmacovigilance at enterprises and persons authorized for pharmacovigilance objectively assessed their practical knowledge and skills in the field of drug safety. Moreover, 42 (72%) respondents believe that they do not need to update their knowledge on pharmacovigilance, whereas 51 (87%) people successfully passed the proposed survey on knowledge of current legislation. Employees of senior positions showed higher knowledge in the field of pharmacovigilance. Specialists and senior pharmacovigilance specialists need to increase their level of professional knowledge, and they are aware of the need for further training.


2 October 2021 in Safety and Risk of Pharmacotherapy
Verified
Journal Article
Open access
PDF file
ATAleksandra A Taube
Aleksandra A Taube
MZM. V. Zhuravleva
M. V. Zhuravleva
ТАТ. В. Александрова
Т. В. Александрова
ODO. A. Demidova
O. A. Demidova
IMI. A. Mazerkina
I. A. Mazerkina
Сравнительный анализ межлекарственного взаимодействия антибактериальных препаратов при терапии внебольничной пневмонии

30 October 2019 in "Medical & Pharmaceutical Journal "Pulse"
Verified
Journal Article
Closed access
ATAleksandra A Taube
Aleksandra A Taube
ФУФгбоу Во Санкт-Петербургский Химико-Фармацевтический Университет
Фгбоу Во Санкт-Петербургский Химико-Фармацевтический Университет